We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A second study evaluating the use of the popular heartburn drug famotidine in patients with severe COVID-19 has found that the treatment reduced deaths and the need for intubation. Read More
CanSino Biologics’ experimental COVID-19 vaccine has entered a late-stage trial in Russia, the company leading the study announced yesterday. Read More
Sinopharm’s COVID-19 vaccine generated antibodies at levels on par with some of its competitors, according to early trial data released by scientists connected with the company and other China-based research institutes. Read More
A potential COVID-19 treatment that uses mesenchymal stem cells (MSCs) has flown under the radar thus far, but the therapy has shown promise in early research, and phase 2/3 results that will likely come out in early fall could show that it’s a game changer. Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is developing a weakened strain of SARS-CoV-2 for use in human challenge trials in case they’re needed to fully evaluate COVID-19 vaccine and therapeutic candidates, though the institute says the controversial studies would not replace phase 3 trials. Read More
The FDA expects sponsors of breast cancer trials to include men as well as women and the scarcity of men with the condition is not an acceptable reason for excluding them from a trial, according to a new final guidance from the FDA. Read More